Long peptide vaccination can lead to lethality through CD4+ T cell-mediated cytokine storm

Journal of Immunology

Volumn 185, Issue 2, 2010, Pages 892-901

  Kitamura, Hiroshi ^a,b   Sedlik, Christine ^a,b   Jacquet, Alexandra ^a,b   Zaragoza, Bruno ^a,b   Dusseaux, Mathilde ^a,b   Premel, Virginie ^a,b   Sastre Garau, Xavier ^a   Lantz, Olivier ^a,b  

^a INSTITUT CURIE   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE; EPITOPE; LONG PEPTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SHORT PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CANCER VACCINE; SUBUNIT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BLOOD LEVEL; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE STORM; DENDRITIC CELL; DNA IMMUNIZATION; DOSE RESPONSE; DRUG FATALITY; FEMALE; FLOW CYTOMETRY; LETHALITY; LYMPHOCYTE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHOCK; AMINO ACID SEQUENCE; ANIMAL; C57BL MOUSE; EXPERIMENTAL NEOPLASM; IMMUNOLOGY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MORTALITY; MOUSE MUTANT; MOUSE STRAIN; PATHOLOGY; SURVIVAL RATE; TIME; TRANSGENIC MOUSE; TUMOR CELL LINE; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPES; FEMALE; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; SURVIVAL RATE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES, SUBUNIT;

EID: 77955479142     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000933     Document Type: Article

References (53)

1. Dudley, M. E., and S. A. Rosenberg. 2003. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer 3: 666-675.
2. Gattinoni, L., D. J. Powell, Jr., S. A. Rosenberg, and N. P. Restifo. 2006. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6: 383-393.
3. Harris, M. 2004. Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 5: 292-302. (Pubitemid 38541581)
4. Renard, V., and D. R. Leach. 2007. Perspectives on the development of a therapeutic HER-2 cancer vaccine. Vaccine 25(Suppl 2): B17-B23.
5. Ho, W. Y., J. N. Blattman, M. L. Dossett, C. Yee, and P. D. Greenberg. 2003. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell 3: 431-437.
6. Blattman, J. N., and P. D. Greenberg. 2004. Cancer immunotherapy: a treatment for the masses. Science 305: 200-205.
7. Rosenberg, S. A., N. P. Restifo, J. C. Yang, R. A. Morgan, and M. E. Dudley. 2008. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8: 299-308.
8. Hunder, N. N., H. Wallen, J. Cao, D. W. Hendricks, J. Z. Reilly, R. Rodmyre, A. Jungbluth, S. Gnjatic, J. A. Thompson, and C. Yee. 2008. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N. Engl. J. Med. 358: 2698-2703.
9. Hodi, F. S., and D. E. Fisher. 2008. Adoptive transfer of antigen-specific CD4+ T cells in the treatment of metastatic melanoma. Nat. Clin. Pract. Oncol. 5: 696-697.
10. Toes, R. E., F. Ossendorp, R. Offringa, and C. J. Melief. 1999. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189: 753-756.
11. Mumberg, D., P. A. Monach, S. Wanderling, M. Philip, A. Y. Toledano, R. D. Schreiber, and H. Schreiber. 1999. CD4(+) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-gamma. Proc. Natl. Acad. Sci. USA 96: 8633-8638.
12. Ossendorp, F., R. E. Toes, R. Offringa, S. H. van der Burg, and C. J. Melief. 2000. Importance of CD4(+) T helper cell responses in tumor immunity. Immunol. Lett. 74: 75-79.
13. Qin, Z., and T. Blankenstein. 2000. CD4+ T cell - mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12: 677-686.
14. Corthay, A., D. K. Skovseth, K. U. Lundin, E. Røsjø, H. Omholt, P. O. Hofgaard, G. Haraldsen, and B. Bogen. 2005. Primary antitumor immune response mediated by CD4+ T cells. Immunity 22: 371-383. (Pubitemid 40387478)
15. Guerder, S., and P. Matzinger. 1992. A fail-safe mechanism for maintaining self-tolerance. J. Exp. Med. 176: 553-564.
16. Shirai, M., C. D. Pendleton, J. Ahlers, T. Takeshita, M. Newman, and J. A. Berzofsky. 1994. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs. J. Immunol. 152: 549-556.
17. Partidos, C. D., P. Vohra, and M. W. Steward. 1996. Induction of measles virus-specific cytotoxic T-cell responses after intranasal immunization with synthetic peptides. Immunology 87: 179-185.
18. Hiranuma, K., S. Tamaki, Y. Nishimura, S. Kusuki, M. Isogawa, G. Kim, M. Kaito, K. Kuribayashi, Y. Adachi, and Y. Yasutomi. 1999. Helper T cell determinant peptide contributes to induction of cellular immune responses by peptide vaccines against hepatitis C virus. J. Gen. Virol. 80: 187-193.
19. Bristol, J. A., C. Orsini, P. Lindinger, J. Thalhamer, and S. I. Abrams. 2000. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. Cell. Immunol. 205: 73-83.
20. Ossendorp, F., E. Mengedé, M. Camps, R. Filius, and C. J. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187: 693-702.
21. Hung, K., R. Hayashi, A. Lafond-Walker, C. Lowenstein, D. Pardoll, and H. Levitsky. 1998. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188: 2357-2368.
22. Perez-Diez, A., N. T. Joncker, K. Choi, W. F. Chan, C. C. Anderson, O. Lantz, and P. Matzinger. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354. (Pubitemid 46890556)
23. Joncker, N. T., J. Helft, A. Jacquet, V. Premel, and O. Lantz. 2006. Intratumor CD4 T-cell accumulation requires stronger priming than for expansion and lymphokine secretion. Cancer Res. 66: 5443-5451.
24. Perez-Diez, A., P. J. Spiess, N. P. Restifo, P. Matzinger, and F. M. Marincola. 2002. Intensity of the vaccine-elicited immune response determines tumor clearance. J. Immunol. 168: 338-347.
25. Parmiani, G., C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F. M. Marincola, and A. Anichini. 2002. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J. Natl. Cancer Inst. 94: 805-818.
26. Celis, E. 2002. Getting peptide vaccines to work: just a matter of quality control? J. Clin. Invest. 110: 1765-1768.
27. Toes, R. E., R. J. Blom, R. Offringa, W. M. Kast, and C. J. Melief. 1996. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J. Immunol. 156: 3911-3918.
28. Toes, R. E., R. Offringa, R. J. Blom, C. J. Melief, and W. M. Kast. 1996. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc. Natl. Acad. Sci. USA 93: 7855-7860.
29. Rosenberg, S. A., J. C. Yang, and N. P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
30. Slingluff, C. L., Jr., and D. E. Speiser. 2005. Progress and controversies in developing cancer vaccines. J. Transl. Med. 3: 18.
31. Srinivasan, M., S. Z. Domanico, P. T. Kaumaya, and S. K. Pierce. 1993. Peptides of 23 residues or greater are required to stimulate a high affinity class II-restricted T cell response. Eur. J. Immunol. 23: 1011-1016.
32. Sercarz, E. E., and E. Maverakis. 2003. Mhc-guided processing: binding of large antigen fragments. Nat. Rev. Immunol. 3: 621-629.
33. Zwaveling, S., S. C. Ferreira Mota, J. Nouta, M. Johnson, G. B. Lipford, R. Offringa, S. H. van der Burg, and C. J. Melief. 2002. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol. 169: 350-358.
34. Bijker, M. S., S. J. van den Eeden, K. L. Franken, C. J. Melief, S. H. van der Burg, and R. Offringa. 2008. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur. J. Immunol. 38: 1033-1042.
35. Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van der Meer, A. P. Vloon, J. W. Drijfhout, A. R. Wafelman, J. Oostendorp, G. J. Fleuren, et al. 2008. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14: 169-177.
36. Welters, M. J., G. G. Kenter, S. J. Piersma, A. P. Vloon, M. J. Löwik, D. M. Berends-van der Meer, J. W. Drijfhout, A. R. Valentijn, A. R. Wafelman, J. Oostendorp, et al. 2008. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14: 178-187.
37. Kenter, G. G., M. J. Welters, A. R. Valentijn, M. J. Lowik, D. M. Berends-van der Meer, A. P. Vloon, F. Essahsah, L. M. Fathers, R. Offringa, J. W. Drijfhout, et al. 2009. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361: 1838-1847.
38. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377.
39. Suntharalingam, G., M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, and N. Panoskaltsis. 2006. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018-1028.
40. Liu, F., R. Feuer, D. E. Hassett, and J. L. Whitton. 2006. Peptide vaccination of mice immune to LCMV or vaccinia virus causes serious CD8 T cell-mediated, TNF-dependent immunopathology. J. Clin. Invest. 116: 465-475.
41. Lantz, O., I. Grandjean, P. Matzinger, and J. P. Di Santo. 2000. Gamma chain required for naïve CD4+ T cell survival but not for antigen proliferation. Nat. Immunol. 1: 54-58.
42. Joncker, N. T., M. A. Marloie, A. Chernysheva, C. Lonchay, S. Cuff, J. Klijanienko, B. Sigal-Zafrani, A. Vincent-Salomon, X. Sastre, and O. Lantz. 2006. Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int. J. Cancer 118: 1205-1214.
43. Helft, J., A. Jacquet, N. T. Joncker, I. Grandjean, G. Dorothée, A. Kissenpfennig, B. Malissen, P. Matzinger, and O. Lantz. 2008. Antigen-specific T-T interactions regulate CD4 T-cell expansion. Blood 112: 1249-1258.
44. Homann, D., L. Teyton, and M. B. Oldstone. 2001. Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat. Med. 7: 913-919.
45. Piguet, P. F., C. Vesin, J. Guo, Y. Donati, and C. Barazzone. 1998. TNF-induced enterocyte apoptosis in mice is mediated by the TNF receptor 1 and does not require p53. Eur. J. Immunol. 28: 3499-3505.
46. Nchinda, G., J. Kuroiwa, M. Oks, C. Trumpfheller, C. G. Park, Y. Huang, D. Hannaman, S. J. Schlesinger, O. Mizenina, M. C. Nussenzweig, et al. 2008. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J. Clin. Invest. 118: 1427-1436.
47. Bilsborough, J., C. Uyttenhove, D. Colau, P. Bousso, C. Libert, B. Weynand, T. Boon, and B. J. van den Eynde. 2002. TNF-mediated toxicity after massive induction of specific CD8+ T cells following immunization of mice with a tumor-specific peptide. J. Immunol. 169: 3053-3060. (Pubitemid 35013149)
48. Sriskandan, S., and D. M. Altmann. 2008. The immunology of sepsis. J. Pathol. 214: 211-223.
49. Chapman, P. B., T. J. Lester, E. S. Casper, J. L. Gabrilove, G. Y. Wong, S. J. Kempin, P. J. Gold, S. Welt, R. S. Warren, H. F. Starnes, et al. 1987. Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. J. Clin. Oncol. 5: 1942-1951.
50. Weichselbaum, R. R., D. W. Kufe, S. Hellman, H. S. Rasmussen, C. R. King, P. H. Fischer, and H. J. Mauceri. 2002. Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol. 3: 665-671.
51. Speetjens, F. M., P. J. Kuppen, M. J. Welters, F. Essahsah, A. M. Voet van den Brink, M. G. Lantrua, A. R. Valentijn, J. Oostendorp, L. M. Fathers, H. W. Nijman, et al. 2009. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 15: 1086-1095.
52. Vyas, J. M., A. G. Van der Veen, and H. L. Ploegh. 2008. The known unknowns of antigen processing and presentation. Nat. Rev. Immunol. 8: 607-618.
53. Khan, S., M. S. Bijker, J. J. Weterings, H. J. Tanke, G. J. Adema, T. van Hall, J. W. Drijfhout, C. J. Melief, H. S. Overkleeft, G. A. van der Marel, et al. 2007. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J. Biol. Chem. 282: 21145-21159.